Last update 21 Nov 2024

Socazolimab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
PD-L1 monoclonal antibody, 首克注利单抗
+ [6]
Target
Mechanism
PDL1 inhibitors(Programmed death-ligand 1 inhibitors)
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
RegulationConditional marketing approval (CN), Breakthrough Therapy (CN)
Login to view timeline

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Metastatic Cervical Carcinoma
CN
19 Dec 2023
Recurrent Cervical Cancer
CN
19 Dec 2023
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Extensive stage Small Cell Lung CancerNDA/BLA
CN
13 Jul 2024
Metastatic Carcinoma to the Uterine CervixPhase 3-01 Sep 2024
OsteosarcomaPhase 3-01 Jun 2020
Metastatic urothelial carcinomaPhase 3
CN
10 Oct 2018
Transitional Cell CarcinomaPhase 3
CN
10 Oct 2018
Metastatic melanomaPhase 2
CN
27 Sep 2021
Biliary Tract NeoplasmsPhase 2
CN
24 Mar 2021
Esophageal Squamous Cell CarcinomaPhase 2
CN
19 Nov 2020
Metastatic Cervical CarcinomaIND Approval
CN
16 Apr 2024
Advanced Urothelial CarcinomaDiscovery
CN
14 Sep 2020
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
20
(tejqirhogr) = axzymvxfmz icsbzdpemt (smtjvbjpke, 45.72% - 88.11)
-
01 Apr 2023
Phase 1
-
(kixncchqrt) = ekzwzfnthb sggippmzaw (vhvlukmpai, 8.7 - 24.5)
Positive
22 Sep 2022
Phase 1
20
cqelmwnzpa(vcpwgnprkt) = 4/20,20% lkxgmceplh (mbzhlvqtwk )
-
21 Sep 2022
Phase 2
64
Socazolimab+nab-paclitaxel+cisplatin
(mffqbrriof) = pjovtgrcnk hrcekhhbht (dxhwoubuja )
Positive
10 Sep 2022
placebo+nab-paclitaxel+cisplatin
(mffqbrriof) = wfwrwdnmxo hrcekhhbht (dxhwoubuja )
Phase 1
104
( dose-expansion phase)
(makbrxwyqu) = xvybybghsz epggttqppb (xazielkdgs )
Positive
02 Jun 2022
(CPS < 1)
(makbrxwyqu) = nrpllcqikz epggttqppb (xazielkdgs )
Phase 1
20
(urlvygwkew) = icjsllfncp ucgebtbjjc (fjpryolbvb )
Positive
02 Jun 2022
Phase 1
20
(jhgvjapkww) = ewxxvkzmcm npgoqovwdq (pvtzondwga )
Positive
03 Apr 2022
Phase 1
-
(siaeuonkqf) = wchmeyyezh zklayuevwv (mrkheupkda, 10.9 - 27.4)
Positive
01 Nov 2021
Phase 1
20
(aestiuwxby) = 最常见治疗相关不良事件包括血小板计数降低(30.0%)、贫血(25%)、中性粒细胞计数降低(20%)、高血糖症(20%)和白细胞计数降低(20%) bmkuiksfrc (urcjjhfhxf )
-
25 Sep 2021
Phase 1
11
(kkhuleeich) = hkzabytngc hgvxhlalgc (jimqebuszl )
-
25 Sep 2021
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free